Adjuvant chemotherapy of osteogenic sarcoma:progress and perspectives

Abstract

Vincristin and adriamycin were used, and as adjuvant, methotrexate-citovorum factor (MTX-CF). The weekly high dose of this treatment seems more effective than the triweekly program. For practical reasons, such treatment cannot be extended beyond 4 weeks. As most antitumor agents are variably mutagenic, mutant daughter cells are produced, which are drug resistant. With the adjuvant effect 80% of patients survived for 48 months.